Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Hims & Hers Health's Strategic Growth in Weight Loss Market Warrants Buy Rating Despite Regulatory Risks
Deutsche Bank Adjusts Hims & Hers Health Price Target to $16 From $14, Maintains Hold Rating
Buy Rating Affirmed for Hims & Hers Health Amidst Strong Quarterly Performance and Positive Outlook
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating
Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Hims & Hers Health (HIMS) and Amylyx Pharmaceuticals Inc (AMLX)
Deutsche Bank Adjusts Hims & Hers Health Price Target to $14 From $8, Maintains Hold Rating
Hims & Hers Health Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Bruker (BRKR), Hims & Hers Health (HIMS)
Truist Financial Reaffirms Their Hold Rating on Hims & Hers Health (HIMS)
Hims & Hers Health (HIMS) Gets a Hold From Piper Sandler